HIQ Faces Milestone Risks in Victorian Manufacturing Grant Deal

Victorian Grant Anchors HIQ’s Manufacturing Expansion

HIQ Limited (ASX:HIQ) has formalised a non-dilutive funding agreement with the Victorian Government to support a minimum $4.9 million project aimed at expanding its manufacturing and research operations in Victoria. While the exact grant amount remains confidential within a $250,000 to $1.5 million band, this injection is a strategic boost to HIQ’s efforts to scale production of its integrated charger and data transfer systems, alongside advancing its hardware and software capabilities.

The funding aligns with HIQ’s broader strategy to retain its operational headquarters and R&D centre in Victoria while accelerating international sales growth. This move comes on the back of HIQ’s recent commercial momentum, including a 223% sales surge driven by the national rollout of its PROTEQT™ concussion management system and initial international club sales.

Milestone-Linked Support with Long-Term Commitments

The grant agreement, effective until 31 July 2031, ties funding to measurable milestones, requiring HIQ to meet specific obligations to access the full grant. The company faces potential refund obligations if it fails to comply, underscoring the Victorian Government’s intent to ensure tangible outcomes from its investment. This framework reflects a cautious but supportive approach to fostering local advanced manufacturing and R&D capabilities.

HIQ’s Chairman Earl Eddings highlighted the grant as a strong endorsement of the company’s technology platform and growth trajectory. The funding will underpin continued investment in advanced manufacturing equipment, tooling, and product innovation, while also supporting employment growth in Victoria.

Strategic Implications Amid Funding and Growth Dynamics

This government backing arrives amid HIQ’s ongoing capital management efforts, including a recent $1 million loan facility backed by convertible notes to bolster working capital amid funding challenges. The grant complements these financial moves by reducing dilution risk and enabling focused investment in manufacturing scale-up and R&D, critical for sustaining momentum in competitive concussion management technology markets.

HIQ’s PROTEQT™ system, co-developed with Shock Doctor, remains central to its product suite, delivering real-time head impact data through smart mouthguards and analytics platforms. The company’s expanding footprint, including recent international deals and national retail launches, underscores the importance of robust local manufacturing and innovation capacity to meet growing demand and maintain quality control.

Looking ahead, the grant’s milestone conditions and long-term horizon suggest investors should watch how effectively HIQ translates this funding into operational expansion and whether it can meet the performance targets required to secure the full grant value. This development ties into the company’s broader narrative of transitioning from technology validation to commercial execution, a journey marked by recent sales growth and strategic partnerships.